le 21 juillet 2021

As the COVID-19 pandemic shows signs of stabilizing, it is imperative for biopharmaceutical companies to reanalyze and recalibrate promotional strategies to align with healthcare professional (HCP) needs.

This paper provides insights from our 3-wave study on HCPs’ evolving outlooks on care delivery and prescription practices, and how they would like to engage with pharmaceutical reps going forward.

 

Download the Full Report Below

Scroll to Page Bottom Form 
Enabled 
Powered by Translations.com GlobalLink OneLink Software